Herrera-Ruiz D, Wang Q, Gudmundsson OS, Cook TJ, Smith RL, Faria TN and Knipp GT Spatial Expression Patterns of Peptide Transporters in the Human and Rat Gastrointestinal Tracts, Caco-2 In Vitro Cell Culture Model, and Multiple Human Tissues AAPS PharmSci 2001;
3
(1)
article 9
(https://www.pharmsci.org/scientificjournals/pharmsci/journal/01_09.html).
Spatial Expression Patterns of Peptide Transporters in the Human and Rat Gastrointestinal Tracts, Caco-2 In Vitro Cell Culture Model, and Multiple Human Tissues
Submitted: December 7, 2000; Accepted: February 22, 2001; Published: March 9, 2001
Dea Herrera-Ruiz1, Qing Wang1, Olafur S. Gudmundsson2, Thomas J. Cook1, Ronald L. Smith3, Teresa N.Faria3 and Gregory T. Knipp1
1Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ
2Small Molecular Pharmacology, Genentech, South San Francisco, CA
3Exploratory Biopharmaceutics & Drug Delivery, Bristol-Myers Squibb Research Institute, New Brunswick, NJ
Correspondence to: Gregory T. Knipp Telephone: 732-445-2669 Facsimile: 732-445-3134 E-mail: gknipp@cop.rutgers.edu
|
Keywords: Peptide Transport PepT1 PTR3 PHT1 HPT-1 GI Tract Human Digestive cDNA Panel Human Tissue cDNA Panel Caco-2 Cells
|
Abstract
This study sought to identify the spatial patterns of
expression of peptide transporter 1 (PepT1), peptide transporter 3 (PTR3),
peptide/histidine transporter 1 (PHT1), and the human peptide transporter 1
(HPT-1) mRNA in complementary DNA (cDNA) libraries of the human and rat
gastrointestinal tracts (GIT), Caco-2 in vitro cell culture model, and in a
human multiple tissue panel. Human PTR3 and PHT1 are putative peptide
transporters recently discovered. Using sequence-specific primers designed to
amplify regions of PepT1, PTR3, PHT1, and HPT-1, we were able to identify the
expression of mRNA for each of these transporters in human cDNA panels
(Clontech, Palo Alto, CA), the rat GIT, and in Caco-2 cDNA libraries by the
polymerase chain reaction (PCR) and Southern Blot analysis. These studies
suggest that in the human GIT, PepT1 appears to be localized predominantly in
the duodenum, with decreasing expression in the jejunum and ileum. In contrast,
PTR3 and HPT-1 were widely expressed in the human GIT, with predominant
expression in the different regions of the colon. PHT1 appeared to be expressed
in low levels throughout the human GI tract.
Interestingly, the mRNAs for all 4 peptide transporters were expressed in Caco-2
cells throughout 30 days of culture. PepT1, PTR3, PHT1, and HPT-1 were also
widely expressed in the rat GIT. Human tissue cDNA panel screening suggests that
PTR3 and PHT1 are more uniformly expressed, whereas PepT1 and HPT-1 demonstrated
site-specific expression. These results suggest that PepT1, PTR3, PHT1, and
HPT-1 all may act to facilitate the diffusion of peptides and peptide-based
pharmaceuticals in the GIT. PTR3, PHT1, and HPT-1 expressions in Caco-2 cell
monolayers strongly suggest that their function needs to be further elucidated
and their contribution to peptide transport not ignored. Taken together, these
results demonstrate the potential for molecular biological characterization in
localizing active transporter systems that can potentially be targeted for
enhancing the absorption of peptide-based pharmaceuticals.
Introduction
The use of in vitro and in situ models to assess
intestinal permeation characteristics of peptides and peptide-based drugs has
become commonplace in many laboratories. However, it should not be taken for
granted that the actual intestinal enterocyte barrier has differing levels of
expression and transcriptional regulation of genes than found in these in vitro
or in situ models. With recent advances in molecular biology leading to
the development of several techniques, including microarray technology, reverse
transcriptase polymerase chain reaction (RT-PCR), complementary DNA (cDNA)
libraries, and multiple-tissue Northern blots, the ability for scientists to
screen several tissues for messenger RNA (mRNA) expression has become
commonplace in many laboratories. Several commercially available sources of cDNA
panels derived from numerous human, rat, and mouse tissues exist. In this study,
we have used a recently developed human digestive system cDNA panel (Clontech,
Palo Alto, CA) derived from each segment of the human digestive tract (in order:
esophagus, stomach, duodenum, jejunum, ileum, ileocecum, cecum, ascending colon,
transverse colon, descending colon, and rectum).
These developments provide pharmaceutical scientists access to
strategies for quickly elucidating spatial patterns of expression of mRNAs
corresponding to genes/proteins that may be of considerable interest. It is
apparent that the formulation scientist can now rapidly and critically assess a
target protein's (either receptor or transporter) expression in tissue samples
and tailor formulations to optimize delivery of agents to the regions of optimal
expression. This may even be expanded to investigate regions where proteins that
limit bioavailability of a therapeutic agent could be avoided (ie, multidrug
resistant proteins) by delivery of substrates to regions where these proteins
are least expressed. We have used such an approach to characterize the molecular
expression patterns of peptide transporters in the human and rat
gastrointestinal tracts (GIT), Caco-2 cell monolayers, and in multiple human
tissues.
The therapeutic use of peptide-based pharmaceuticals for many
disorders has been the focus of numerous papers 1-6 . Peptides and peptide-based
agents, due largely to multiple side chain functionalities, tend to be polar
molecules that do not readily traverse biological barriers via passive diffusion1, 7-11 . In the past several years, considerable work has been performed to
explore the active peptide transporters that are known to facilitate peptide
transport5, 12, 13 . Several human small oligopeptide transporters are now known,
including peptide transporter 1 (PepT1) and human intestinal peptide transporter
1 (HPT1)5, 14-16 . PepT1 belongs to a superfamily known as proton oligopeptide
transporter (POT), where all the known peptide transporters, with the exception
of HPT1 (a cadherin family member), are grouped13, 27 . Of these transporters, PepT1 has
gained the most focus and has been theorized to be the predominant peptide
transporter in the GIT1, 5, 17,18 . The focus is on PepT1 because it was the first
peptide transporter characterized and because of its high expression in the rat
GIT and Caco-2 cell culture model, a human colon-derived adenocarcinoma cell
line that has been widely used as anin vitro model of the gastrointestinal
enterocytes19-21 . More recently, HPT-1 has been identified in Caco-2 cells
16, 22-25 , but as yet has not received the same level of research as PepT1.
Until recently, only 2 POT genes had been identified in mammalian species: hPepT1 and hPepT2. Putative peptide transporter 3 (PTR3) is a
newly reported transporter (GenBank Accession number AB020598) that has not been
exhaustively studied; therefore, little is known about its functional
significance. PTR3 is a human protein that shares homology with members of the
PTR family26-30 . Release of the human genome has opened the search for new
potential drug transporters. A recent report has shown evidence of the presence
of 2 potentially new peptide transporters28 . The cDNA sequence predicted for
one of these transporters is almost identical to the one submitted in the
GenBank for PTR3-Sadee and colleagues28 named it hPHT2.
Peptide/histidine transporter 1 (PHT1) has been initially
identified and cloned from the rat brain29 . Our30 and Dr. Wolfgang Sadee's
(personal communication) laboratories recently cloned the human PHT1 isoform and
have begun the analysis of its expression in several human and rat tissues. We
included the putative transporters PTR3 and PHT1 in our survey to present
a current view of potential peptide transporters in the human GIT and models
most often used to assess intestinal peptide permeability. In addition, we
cannot rule out that other peptide transporters may exist in the GIT that have
yet to be identified.
Elucidating these transporters' gene expression patterns will
provide essential information for formulation scientists to develop rationally
targeted drug delivery systems. In addition, further functional characterization
of these transporters will provide medicinal chemists with insights into the
essential functional groups that will enable them to synthesize agents with high
specificity for these transporters.
Materials and Methods
Materials
Nonessential amino acids, fetal bovine serum, trypsin/EDTA,
penicillin and streptomycin, and Dulbecco's Modified Eagle Medium (DMEM) were
purchased from Mediatech, Inc. (Herndon, VA). The Human Digestive System and
Human Multiple Tissue cDNA Panels were purchased from Clontech (Palo Alto, CA).
Taq DNA polymerase was purchased from New England Biolabs (Beverly, MA). Tri
Reagent was obtained from the Sigma Chemical Company (St Louis, MO). RT-PCR kits
were obtained from Life Technologies (Gaithersburg, MD). The North2South Biotin
Random Prime Kit used in the preparation of DNA probes and the North2South
Chemiluminescent Nucleic Acid Hybridization and Detection Kit used for Southern
Blot analysis were purchased from Pierce (Rockford, IL).
Animals and tissue collection
Female Holtzman rats (6 months old) were
obtained from Harlan Sprague-Dawley (Indianapolis, IN). The animals (200 g)
were housed in an environmentally controlled facility, with lights on from
0600 to 2000 hours, and were allowed free access to food and water. Tissue
dissections were performed and small and large intestinal segments were obtained
according to the standard protocol for identifying the different sections of the
GIT31 . After isolation of the tissues, we proceeded to remove the end sections
of each sample, saving only the middle portion of each region to avoid
contamination from other segments.
On isolation, the tissues were frozen in liquid nitrogen and
stored at -80°C until analyzed.
Cell Culture
The Caco-2 cell line was obtained from the American Type
Culture Collection (Rockville, MD). The cells were cultured as described
previously21 . The cells were grown in 75 cm2 culture flasks (Corning, Inc,
Corning, NY), in culture medium that consisted of DMEM with 100 mg/mL
penicillin, 100 mg/mL streptomycin, 1% nonessential amino acids, and 10% fetal
bovine serum. Cells were maintained at 37°C in an atmosphere of 95% relative
humidity and 5% CO2. The culture medium was replaced every other day for the
first week and daily thereafter. Cells used in this study were between passages
30 and 40.
RT-PCR and Electrophoresis
The Human Digestive cDNA Panel was used to determine the
spatial patterns of expression of each transporter in the human GIT. Total RNA
was isolated from rat dissected tissues and from 4-, 10-, 15-, 20-, 25-, and
30-day-old Caco-2 cells with the TRI reagent as described by
Chomczynski and Sacchi32 . Five µg of total RNA and 0.5 µg of oligo-(dT) were
used for the reverse transcriptase reaction. RT-PCR was performed with a portion
of the reverse transcriptase-generated cDNA and primers (Table 1 ) specific for
PepT1, PTR3, PHT1, and HPT-1. Human β-actin primers
were obtained from Maxim Biotech, Inc (San Francisco, CA). The PCR reaction was
performed using optimized PCR conditions (denature: 94°C for 1 minute; annealing: 55°C for
2 minutes; extension: 72°C for 2 minutes for PepT1 and
HPT1; and denature: 94°C for 1 minute; annealing:
65°C for 2 minutes; extension: 72°C for 2 minutes for PTR3 and PHT1) using a Perkin-Elmer
Thermocycler (Model 480, Norwalk, CT). Reaction products were
electrophoretically separated in 1.4% agarose gels. Ethidium-stained bands and
densitometry measurements were detected using a NucleoTech 920 Chemiluminescence
detection system (NucleoTech Corporation, San Mateo, CA). The molecular weight
for each band was calculated using a 100-bp molecular weight ladder as a
reference (PanVera Corporation, Madison, WI). Each RT-PCR gene expression
analysis was performed at least 3 times.
Southern Analysis
The electrophoretically separated reaction products in the
agarose gel were transferred to nylon membranes (Ny+, Millipore, Bedford, MA), and probed with biotin-labeled PepT1, PTR3, PHT1, and HPT1 cDNAs,
respectively. The human PepT1 cDNA was kindly donated by Dr Frederick H. Leibach
(Medical College of Georgia, Augusta), and HPT-1 full sequence was amplified
from Caco-2 cells and confirmed by sequencing analysis, while the PTR3 and PHT1
partial sequence was obtained from clones 668165 and 325557, respectively
(I.M.A.G.E. Consortium, https://image.llnl.gov/ ). Rat PepT1 probe was obtained using
a 700-bp fragment of the rPepT1 cDNA (kindly donated by Dr Matthias A. Hediger,
Harvard Medical School, Boston, MA). Southern analysis of blots for
rPTR3, rat HPT1, and rat PHT1 were performed using the same probes as for their
human isoforms. Chemiluminescence measurements were analyzed using a NucleoTech
920 Chemiluminescence detection system (San Mateo, CA).
Results
Table 1 shows the primers designed to specifically amplify cDNA
encoding regions of human PepT114 , PTR3 (GI: AB020598), PHT128 , and HPT-116 in the human GIT. Table 1 also shows the sequence-specific primers for the
corresponding homologous rat isoforms of these proteins that were designed to
specifically amplify cDNA encoding regions of rat PepT133 , rat PHT1 29 , and
rat PT-134 . All PCR experiments were performed and analyzed in the linear range
of amplification for each primer set (data not shown). We were unable to design
rat-specific primers for PTR3 since only the human sequence has been reported.
However, using the 2 separate sets of human PTR3 primers (data not shown), we
were able to amplify fragments that were identical to the size predicted by the
human cDNA sequence, respectively. These results suggest a high homology between
the human and rat sequences. Through Southern Blot analysis it was shown that
the rat PTR3 hybridizes to the human isoform fragment; we are currently
sequencing the rat PTR3 fragments to determine their exact sequence.
Analysis of the human PHT1 expression was first done using rat
sequence primers in the human tissues. After identifying that some of these
primers amplified products with a sequence highly homologous to the rat PHT1
sequence, we derived a preliminary human PHT1 sequence from human expressed
sequences tags highly homologous to the rat PHT1 cDNA29 . The remaining
primers were designed based on the reported coding region DNA sequences and
their specificity was confirmed by nucleotide BLAST search
computer analysis. In each case the primers were confirmed to be highly specific
for each particular transporter, with no significant homology to any other known
sequences in human or rat tissue. However, HPT-1 PCR analysis amplified several
products that may be related to the cadherin family-cell adhesion proteins that
are highly homologous to HPT-116 . Southern analysis for this particular blot
was difficult to perform because of the hybridization of the HPT-1 probe with
some other bands present. Identification of the HPT-1-specific PCR product was
performed by sequencing analysis of the amplified product either from the cDNA
panels or from the Caco-2 cells, respectively (data not shown).
In Figure 1 , the results for the RT-PCR amplification and
Southern Blot analysis of the human isoforms of PepT1, PTR3, PHT1, and HPT-1 in
the human digestive tract cDNA panel are shown. The results of our studies
suggest that PepT1 is predominantly expressed in the human duodenum, with
decreasing expression found in the jejunum and the ileum (Figure 1 ).
Interestingly, PTR3 expression and HPT-1 expression were demonstrated in several
regions of the human GIT, and were not predominantly restricted to the duodenum
as was PepT1. Although the results do not infer quantitation or functional
significance for direct comparison, they do suggest that PTR3 and HPT-1 should
be further characterized to properly assess their respective importance in the
facilitation of oligopeptide and peptide-based drug diffusion in the human GIT.
According to our RT-PCR analysis, PHT1 is not highly expressed in the GIT as
confirmed by Southern Blot analyses, which showed a faint band of expression
might be present. However, the levels of protein expression and the functional
significance of PHT1 need to be determined to properly assess PHT1's role.
The results for the RT-PCR amplification and Southern Blot
analysis of the rat isoforms of PepT1, PTR3, PHT1, and PT-1 in the different
regions of the rat GIT are shown in Figure 2 . These results suggest that PepT1
and PHT1 are widely expressed throughout the rat GIT (Figure 2 ), in contrast
with the regional pattern of expression found in the human GIT panel (Figure 1 ).
Consistent with the expression patterns elucidated in the human GIT cDNA panel,
both PTR3 and HPT-1 also were expressed throughout the rat GIT.
In Figure 3 , the results for the RT-PCR amplification and
Southern Blot analysis of the human isoforms of PepT1, PTR3, PHT1, and HPT-1 are
shown in the Caco-2 cell model. Each of these transporters were demonstrated to
be present throughout each of the days of culture of the Caco-2 cells. These
results suggest that all 4 transporters may act to contribute to the observed
transport kinetics measured for peptide and peptide-based pharmaceuticals across
Caco-2 monolayers.
Figure 4 represents the results for the RT-PCR amplification
and Southern Blot analysis of the human isoforms of PepT1, PTR3, PHT1, and HPT-1
in the multiple tissue human cDNA panels. The results suggest that PepT1 mRNA is
predominantly expressed in the human liver and pancreas. Lower levels of PepT1
expression were observed in the kidney, placenta, and prostate. HPT-1 expression
was observed in the colon, skeletal muscle, and faintly in the small intestine.
Surprisingly, PTR3 and PHT1 expression was determined to be fairly uniform in
the human cDNA panel. PTR3 expression was observed in all of the tissues present
in the panel with the exception of the prostate, while PHT1 expression was
determined particularly in liver, placenta, prostate, and thymus.
Discussion
The transport of most nutrient classes across biological
barriers is facilitated by several different transporter classes with
overlapping specificities35-42 ; however, for oligopeptides and peptide-based
drugs, transport is believed to be predominantly facilitated by either PepT1 or
PepT2. Our results suggest that there may actually be other oligopeptide
transporters present in these tissues that remain to be functionally
characterized. The results of these studies also suggest that more emphasis
needs to be placed on identifying other potential peptide transporter isoforms
for peptide and peptide-based drug-screening purposes.
The expression patterns of the human and rat isoforms of PepT1,
PHT1, and HPT-1 transporters in the GIT have been partially described before
14, 25, 28,29 . However, these studies did not directly compare the regional
expression of PepT1, PTR3, PHT1, and HPT-1 simultaneously, due in part to the
fact that several of the transporters have only recently been elucidated. In
this study, we established the simultaneous expression patterns of several
peptide transporters in both whole human and rat GITs, in multiple human
tissues, and in the Caco-2 cell culture model. Furthermore, the initial
comparison of these transporters' expression by using the same tissue sources
and comparable experimental conditions provides a more adequate assessment of
their physiological relevancy. The results reported in this article are being
used to better establish an understanding and framework for further studies that
can completely assess the physiological and functional significance of these
peptide transporters. Only on this complete characterization can the advantages
and disadvantages of using different models to assess human intestinal peptide
absorption by these transporters be fully understood.
In these studies, we demonstrated the human digestive
tract mRNA expression of PepT1, PTR3, PHT1, and HPT-1. These results suggest
that the relative importance of PepT1 in facilitating peptide and peptide-based
drug diffusion may be overstated. HPT-1 and the putative peptide
transporters PTR3 and PHT1 are also expressed in the human GIT, and their
relative importance in the facilitation of oligopeptide and peptide-based drug
transport must be characterized to properly assess their respective importance.
These results do not rule out the possibility of the existence of other
transporters and do not directly relate to transporter function either; however,
they do provide strong suggestive evidence that more than one peptide
transporter is responsible for facilitating peptide and peptide-based drug
permeation across the GI barrier, as has been theorized by others27,28 .
RT-PCR is a highly sensitive technique, which is readily
used to specifically amplify a signal from mRNA found in a tissue/cell RNA
sample. Based on this observation, we used RT-PCR to investigate the expression
of several peptide transporters from identical tissue sources. Several
differences have been observed between our studies and those already reported by
others14, 28,29 . These differences may arise in part from the sensitivity of
the RT-PCR experiment (when contrasted with Northern Blot analysis) and may be
due to differences in tissue sources.
The results in Figure 2 demonstrate that PepT1, PTR3, PHT1, and
HPT-1 are widely expressed throughout the rat GIT. In particular, the rPepT1
expression pattern characterized in this study differs with the expression
analysis reported by others42 where a Northern Blot analysis showed localized
expression in the small intestine. We attribute these discrepancies to the
different sensitivities found between the RT-PCR technique and the Northern Blot
analysis. The elucidated patterns of expression of these transporters in
the rat GIT suggest that the use of rat intestinal segments for in situ /in vitro
perfusion studies investigating peptide and peptide-based drug diffusion may not
accurately mimic the corresponding regions of the human GIT. Therefore,
extrapolation of peptide and peptide-based drug transport values measured in the
rat model must be taken in context with the differences in the patterns of
expression of the peptide transporters. In addition, because cross-species
differences exist in the primary sequences of the different peptide transporters
14,16, 29, 33,34 , one must recognize that there may exist kinetic differences
between the ability of human peptide transporter isoforms and their rat
counterparts to facilitate peptide and peptide-based drug transport.
Contrasting the expression of PepT1, PTR3, PHT1, and HPT1 in
the human GIT with the observed expression in the Caco-2 cell culture model, it
becomes readily apparent that the Caco-2 cells also do not appear to be
representative of any one region of the human GIT. The expression of each
transporter suggests that peptide and peptide-based drug transport measured
across this model is potentially attributable to several transporters. Efforts
must be made to completely characterize the function of each transporter and to
delineate their respective contributions to an overall assessed permeability.
In addition, using in vitro models to assess intestinal
permeation characteristics of peptides and peptide-based drugs must be
undertaken with the understanding that the actual intestinal enterocyte barrier
may have differing levels of expression and transcriptional regulation of
transporters than those observed in in vitro cell lines. Specifically, our
results suggest that expression of these transporters in the Caco-2 cells may
not reflect actual expression in different regions of the human GIT, for
instance, the duodenum versus the colon for PepT1 expression. However, the
significance of our present findings require further investigation into the
elucidation and quantitation of the patterns of expression of each transporter's
mRNA and protein by Northern and Western Blot analysis, respectively.
In Figure 4 , the results for the expression of PepT1, PTR3,
PHT1, and HPT1 in several different human tissues in the Human Multiple Tissue
cDNA panel (ClonTech) are demonstrated. The faint level of PepT1 expression in
the small intestine can be readily explained by the fact that the cDNA source
for this panel came from the entire small intestine, and therefore, the high
expression observed in the duodenum (Figure 1 ) was potentially masked by the
cDNAs derived and grouped from the other small intestinal regions. In addition,
it is somewhat surprising that PTR3 expression and PHT1 expression were found to
be so widespread. Although functional assessments of human PTR3's and PHT1's
ability to facilitate peptide and peptide-based drug transport remain to be
conducted, the widespread expression of both suggests that they may perform a
primary role in the peptide transport in several human tissues.
Our results indicated that these transporters may be more
widely expressed in certain tissues than currently believed28 . For instance,
consider the expression of PHT1 in the human placenta, a tissue source that has
been used for the cloning of the full-sequence of this putative peptide
transporter30 . The use of RT-PCR and Southern Blot analysis provides greater
sensitivity and also can be used to provide further justification for targeting
and assessing regions where greater emphasis needs to be placed in measuring
protein levels and functional significance.
The results of our studies provide insights into the potential
for an integrated approach toward the rational molecular biological and
functional characterization of transporters to aid in the rational design of
peptide-based pharmaceuticals and dosage formulations. In addition, we have
screened both the rat GIT and Caco-2 cell monolayers for expression of PepT1,
PTR3, PHT1, and HPT-1 to assess their ability to mimic human digestive tract for
in vitro and in situ drug screening. Elucidating the patterns of gene
expression of these transporters will, in our opinion, provide essential
information for formulation scientists to develop rationally targeted drug
delivery systems to potentially increase oral bioavailability.
Conclusion
Our studies provide insights into potential pathways and the
regional significance of peptide and peptide-based drug permeation in the human
digestive tract. These results suggest that PTR3 and HPT-1 may be the
predominant transporters for peptide and peptide-based pharmaceuticals that are
formulated in an enteric-coated or controlled-release manner. HPT-1 and the
putative peptide transporters PTR3 and PHT1 may also play significant roles in
facilitating transport across Caco-2 cell monolayers; they should not be
ignored. In addition, PepT1 appeared to be predominantly expressed in the
duodenum and may only be important for facilitating peptide and peptide-based
pharmaceuticals that are rapidly released in the GI tract. Last, these results
demonstrate the potential for using a multiple tissue array technology in the
design of targeted formulations of actively transported pharmaceuticals.
Acknowledgements
We would like to thank the technical assistance provided by Ms
Nesreen El-Toukhy. This work was supported in part by research grants from
Bristol-Myers Squibb Corporation, the American Association of Colleges of
Pharmacy, and research funds provided by Rutgers University College of Pharmacy.
Dea Herrera-Ruiz is a recipient of a Fulbright-CONACyT Graduate Student
Fellowship.
References
1.
Pauletti GM, Gangwar S, Knipp GT, et al. Structural requirements for intestinal absorption of peptide drugs. J Cont Rel. 1996;41:3-17.
2.
Rosenberg SH, Kleinert HD. Renin inhibitors. Pharm Biotechnol. 1998;11:7-28.
[PUBMED]
3.
al-Obeidi F, Hruby VJ, Sawyer TK. Peptide and peptidomimetic libraries: molecular diversity and drug design. Mol Biotechnol. 1998;9:205-223.
[PUBMED]
4.
Doring F, Walter J, Will J, et al. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest. 1998;101:2761-2767.
[PUBMED]
5.
Oh DM, Han HK, Amidon GL. Drug transport and targeting: intestinal transport. Pharm Biotechnol. 1999;12:59-88.
[PUBMED]
6.
Hadley ME, Hruby VJ, Blanchard J, et al. Discovery and development of novel melanogenic drugs: Melatonin-I and -II. Pharm Biotechnol. 1998;11:575-595.
[PUBMED]
7.
Barlow D, Satoh T. The design of peptide analogues for improved absorption. J Contr Rel. 1994;29:283-291.
8.
Burton PS, Conradi RA, Ho NFH, Hilgers AR, Borchardt RT. How structural features influence the biomembrane permeability of peptides. J Pharm Sci. 1996;85:1336-1340.
[PUBMED]
9.
Fricker G, Drewe J. Current concepts in intestinal peptide absorption. J Pept Sci. 1996;2:195-211.
[PUBMED]
10.
Wang W, Borchardt RT, Wang B. Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists. Curr Med Chem. 2000;7:437-453.
[PUBMED]
11.
Bai JP, Amidon GL. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res. 1992;9:969-978.
[PUBMED]
12.
Yang CY, Dantzig AH, Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharm Res. 1999;16:1331-1343.
[PUBMED]
13.
Meredith D, Boyd CAR. Structure and function of eukaryotic peptide transporters. Cell Mol Life Sci. 2000;57:754-778.
[PUBMED]
14.
Liang R, Fei YJ, Prasad PD, et al. Human intestinal H+/peptide cotransporter: cloning, functional expression, and chromosomal localization. J Biol Chem. 1995;270:6456-6463.
[PUBMED]
15.
Fei YJ, Kanai Y, Nussberger S, et al. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 1994;368:563-566.
[PUBMED]
16.
Dantzig AH, Hoskins JA, Tabas LB, et al. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science. 1994;264:430-433.
[PUBMED]
17.
Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998;246:470-475.
[PUBMED]
18.
Tamai I, Nakanishi T, Hayashi K, et al. The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 1997;49:796-801.
[PUBMED]
19.
Audus KL, Bartel RL, Hidalgo IJ, Borchardt RT. The use of cultured epithelial and endothelial cells for drug transport and metabolism. Pharm Res. 1990;7:435-451.
[PUBMED]
20.
Artursson P, Borchardt RT. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res. 1997;14:1655-1658.
[PUBMED]
21.
Knipp GT, Ho NFH, Barsuhn CL, Borchardt RT. Delineation of paracellular diffusion in Caco-2 monolayers effect of perturbation on the transport of model compounds which vary in charge and size. J Pharm Sci. 1997;86:1105-1110.
[PUBMED]
22.
Hu M, Chen J, Zhu Y, Dantzig AH, Stratford RE. Jr., Kuhfeld MT. Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharm Res. 1994;11:1405-1413.
[PUBMED]
23.
Hu M, Zheng L, Chen J, et al. Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin. Pharm Res. 1995;12:1120-1125.
[PUBMED]
24.
Snyder NJ, Tabas LB, Berry DM, Duckworth DC, Spry DO, Dantzig AH. Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells. Antimicrob Agents Chemother. 1997;41:1649-1657.
[PUBMED]
25.
Yang CY. Studies on the human intestinal di-/tripeptide transporter HPT-1 as a potential carrier for orally administered drugs [thesis]. West Lafayette, IN: Purdue University; 1998.
26.
Steiner HY, Naider F, Becker JM. The PTR family: a new group of peptide transporters. Mol. Microbiol. 1995; 16:825-834
[PUBMED]
27.
Graul RC, Sadee W. Sequence alignments of the H(+)-dependent oligopeptide transporter family PTR: Inferences on structure and function of the intestinal PEPT1 transporter. Pharm. Res. 1997; 14(4):388-400.
[PUBMED]
28.
Botka CW, Witting TW, Graul RC, et al. Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci. 2000;2:1-22. Available from: https://www.pharmsci.org/scientificjournals/pharmsci/journal/2.html
29.
Yamashita T, Shimada S, Guo W, et al. Cloning and functional expression of a brain peptide/histidine transporter. J Biol Chem. 1997;272:10205-10211.
[PUBMED]
30.
Herrera-Ruiz D, Wang Q, El-Toukhy N, Gudmundsson OS, and Knipp GT. Gene Expression of a Novel Oligopeptide Transporter in Rat and Human Tissues. 2001 Pharmaceutical Congress of the Americas, Orlando, Florida (March, 2001).
31.
Walker WF, Homberger DG. Anatomy and Dissection of the Rat. New York: W.H. Freeman Co; 1998.
32.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
[PUBMED]
33.
Saito H, Okuda M., Terada T, Sasaki S, Inui K. Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther. 1995;275:1631-1637.
[PUBMED]
34.
Erickson RH, Gum JR Jr, Lindstrom MM, McKean D, Kim YS. Regional expression and dietary regulation of rat small intestinal peptide and amino acid transporter mRNAs. Biochem Biophys Res Commun. 1995;216:249-257.
[PUBMED]
35.
Knipp GT, Liu B, Audus KL, Fujii H, Ono T, Soares MJ. Fatty acid transport regulatory proteins in the developing rat placenta and in trophoblast cell culture models. Placenta. 2000;21:367-375.
[PUBMED]
36.
Knipp GT, Audus KL, Soares MJ. Nutrient transport across the placenta. Adv Drug Del Rev. 1999;38:41-58.
[PUBMED]
37.
Hui TY, Bernlohr DA. Fatty acid transporters in animal cells. Front Biosci. 1997;2:d222-d231.
[PUBMED]
38.
Palacin M, Estevez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev. 1998;78:969-1054.
[PUBMED]
39.
Kahn BB, Flier JS, Regulation of glucose-transporter gene expression in vitro and in vivo. Diabetes Care. 1990;13:548-564.
[PUBMED]
40.
Yao SYM, Ng AML, Muzyka WR, et al. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J Biol Chem. 1997;272:28423-28430.
[PUBMED]
41.
Wang J, Schaner ME, Thomassen S, Su SF, Piquette-Miller M, Giacomini KM. Functional and molecular characteristics of Na+-dependent nucleoside transporters. Pharm Res. 1997; 14:1524-1532.
[PUBMED]
42.
Miyamoto K-I, Shiraga T, Morita K, Yamamoto H, et al. Sequence, tissue distribution and developmental changes in rat intestinal oligopeptides transporter. Biochem Biophys Acta. 1996;1305:34-38.
[PUBMED]
|